<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656200</url>
  </required_header>
  <id_info>
    <org_study_id>JEV SA14-14-2/T cell/01</org_study_id>
    <nct_id>NCT01656200</nct_id>
  </id_info>
  <brief_title>A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2</brief_title>
  <official_title>A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indian Institute of Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indian Institute of Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more
      than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used
      since 2006. JE vaccines give protection by generating a neutralizing antibody response, but
      both naturally exposed persons and patients with JE also have T cell responses. Whether JE
      vaccine SA14-14-2 elicits T cell responses is unknown. This study tests the hypothesis that T
      cell responses are generated in response to JE SA14-14-2 vaccination. The aim of this study
      is to characterize T cell responses to JE vaccine SA14-14-2 in healthy people, and to
      investigate differences in T cell responses between natural exposure, vaccination and
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2.</measure>
    <time_frame>Week 1, week 2, week 4, week 8, 6 months</time_frame>
    <description>Interferon gamma (IFNÎ³) spot forming cells (SFC)/million peripheral blood mononuclear cells (PBMC) at week 2 (peak response)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Titres to Live Attenuated JE SA-14-14-2 Vaccine at Week 4 Post Vaccination.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Neutralizing antibody titres (measured by 50% Plaque reduction neutralisation titre (PRNT50)) at 4 weeks post vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Adverse Events (Graded in Severity 1-4).</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Japanese Encephalitis</condition>
  <condition>Japanese Encephalitis Vaccine</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live attenuated Japanese encephalitis vaccine SA14-14-2</intervention_name>
    <description>Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A male or female adult between 18 and 50 years of age.

          -  Written informed consent.

          -  Free of obvious health problems as established by medical history and history-
             directed physical examination before entering the study.

          -  Expected continuous residence in India during study period, without travel outside
             India

          -  An efficacious method of contraception must be used during the study for women of
             childbearing potential.

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 days preceding administration of SA14-14-2 vaccine, or planned use
             during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within a
             period of six months before vaccination or at any time during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Any antiviral drug therapy within a period of six months before vaccination or at any
             time during the study period.

          -  History of significant allergic disease or reactions likely to be exacerbated by any
             component of the study vaccine, especially allergic disease or reactions to any
             previous dose of any vaccine.

          -  History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis
             vaccine or experimental flavivirus vaccine.

          -  History of documented JE infection.

          -  Detectable anti JE or West Nile neutralizing antibodies in screening tests.

          -  Acute disease at the time of enrollment. Entry into the study may be deferred until
             the illness is resolved.

          -  Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic,
             neurological or renal functional abnormality, as determined by history and physical or
             laboratory examination that is not controlled by drugs.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding administration of vaccine, or planned administration during the study
             period.

          -  Seropositive for HIV, HCV or HbsAg.

          -  Lactation, pregnancy or intention to get pregnant.

          -  History of excessive alcohol consumption, drug abuse or significant psychiatric
             illness.

          -  Any other condition that in the opinion of the investigator would pose a health risk
             to the participant or interfere with the evaluation of the vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof S Vijaya, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indian Institute of Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr V Ravi, MBBS MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health and Neuro Sciences, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indian Institute of Science</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Mental Health and Neurosciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <results_first_submitted>August 18, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indian Institute of Science</investigator_affiliation>
    <investigator_full_name>Prof S Vijaya, Dr. Lance Turtle</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Japanese encephalitis</keyword>
  <keyword>Japanese encephalitis vaccine</keyword>
  <keyword>T lymphocyte</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
          <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2: Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy South Indian Adults resident in Bengaluru, Karnataka State</population>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2: Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="20" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2.</title>
        <description>Interferon gamma (IFNÎ³) spot forming cells (SFC)/million peripheral blood mononuclear cells (PBMC) at week 2 (peak response)</description>
        <time_frame>Week 1, week 2, week 4, week 8, 6 months</time_frame>
        <population>15 participants had data available at the two week time point. 1 withdrew beforehand, 1 declined to donate thew two week blood sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2: Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
          </group>
        </group_list>
        <measure>
          <title>Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2.</title>
          <description>Interferon gamma (IFNÎ³) spot forming cells (SFC)/million peripheral blood mononuclear cells (PBMC) at week 2 (peak response)</description>
          <population>15 participants had data available at the two week time point. 1 withdrew beforehand, 1 declined to donate thew two week blood sample.</population>
          <units>IFNÎ³ SFC/million PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="0" upper_limit="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Antibody Titres to Live Attenuated JE SA-14-14-2 Vaccine at Week 4 Post Vaccination.</title>
        <description>Neutralizing antibody titres (measured by 50% Plaque reduction neutralisation titre (PRNT50)) at 4 weeks post vaccination</description>
        <time_frame>4 weeks</time_frame>
        <population>1 participant withdrew before the 4 week time point, for another the sample was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2: Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Antibody Titres to Live Attenuated JE SA-14-14-2 Vaccine at Week 4 Post Vaccination.</title>
          <description>Neutralizing antibody titres (measured by 50% Plaque reduction neutralisation titre (PRNT50)) at 4 weeks post vaccination</description>
          <population>1 participant withdrew before the 4 week time point, for another the sample was not available for analysis.</population>
          <units>Neutralising antibody titres</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="0" upper_limit="1188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Adverse Events (Graded in Severity 1-4).</title>
        <time_frame>one month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2: Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events (Graded in Severity 1-4).</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
          <description>Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2: Live attenuated Japanese encephalitis vaccine SA14-14-2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever, headache, myalgia, sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fever, myalgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness, Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dizziness for 2-3 seconds a time</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fever, dry cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Lance Turtle</name_or_title>
      <organization>University of Liverpool</organization>
      <phone>+44 151 795 9626</phone>
      <email>lance.turtle@liverpool.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

